Cx Precision Medicine, a groundbreaking diagnostics company founded on the research of Dr. Sid O’Bryant at The University of North Texas Health Science Center at Fort Worth, recently was selected to join the prestigious StartUp Health’s Alzheimer’s Moonshot community.
The recognition solidifies both CxPM and HSC’s place at the forefront of the global effort to drive innovation in Alzheimer’s care and diagnostics.
CxPM, a spinout from O’Bryant’s laboratory at HSC, was founded to advance his pioneering work on blood-based biomarkers for Alzheimer’s disease and other neurodegenerative conditions.
O’Bryant, the founder of CxPM, is also a professor of family medicine at HSC and executive director of HSC’s Institute for Translational Research. His research forms the backbone of CxPM’s mission to improve early detection and treatment strategies for Alzheimer’s.
“I’m excited and humbled by the achievement of the CxPM team,” O’Bryant said. “I embarked on this journey of creating a blood test for Alzheimer’s detection in primary care because of my own clinical and personal experiences. I’m thrilled to see this soon come to fruition in clinics.”
StartUp Health Alzheimer’s Moonshot initiative is dedicated to advancing solutions to prevent, diagnose, and cure Alzheimer’s, a disease affecting more than 55 million people worldwide.
The Alzheimer’s Moonshot Community was launched in early 2024 by StartUp Health with support from organizations such as Gates Ventures and the Alzheimer's Drug Discovery Foundation. Its goal is to accelerate the innovation around Alzheimer’s disease and related dementias by bringing together companies, researchers, and innovators to collaborate across the spectrum of Alzheimer’s care.
HSC maintains a collaborative relationship with CxPM through sponsored research activities, representation on the CxPM board, and prosecution of patent applications in a strong, global intellectual property portfolio.
Joining the Alzheimer’s Moonshot community marks a significant milestone in CxPM’s journey. As the company seeks to expand its operations and raise additional capital, this exclusive program offers invaluable access to a network of investors, collaborators and strategic partners.
By joining the community, CxPM will gain access to mentorship, global collaborations and the opportunity to enhance its impact through partnerships with other innovators focused on Alzheimer’s care.
O’Bryant’s vision and HSC’s ongoing involvement in CxPM have positioned the company as a leader in precision diagnostics for Alzheimer’s disease. This achievement highlights the role of academic research and innovation in addressing one of the world’s most challenging diseases.
“We are deeply honored to be a part of the Alzheimer’s Moonshot initiative,” CxPM CEO Danguole Altman said. “The collaboration between Cx Precision Medicine and HSC has been instrumental in bringing precision diagnostics to Alzheimer’s care. This will enable us to enhance our real-world impact on patients’ lives.”